Reports Q4 revenue $14.9M vs. $11.9M last year. "Iradimed continues a sixth consecutive quarter of reaching record revenue. It’s very rewarding to be part of such growth and witness continued strength in our operating performance, as evidenced once more by our recent fourth quarter and year-ended December 31, 2022, results. Such a performance also allows us to again return value to our shareholders through a special cash dividend. We ended the year on December 31, 2022, with $57.9 million in cash and cash equivalents on our balance sheet and no debt. We believe our remaining cash, after the dividend payout, and future cash flows remain sufficient to fund our operations and investments for our planned growth. Our position in the market grows stronger each quarter, a trend we see continuing. We will continue to operate our business with the same focus on top-line growth and increasing profits as stated in our financial guidance provided earlier this year," said Roger Susi, President, Chief Executive Officer, and Chairman of the Company’s Board of Directors.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IRMD:
- IRADIMED CORPORATION Announces Fourth Quarter and Full Year 2022 Financial Results and Announces Special Cash Dividend
- IRADIMED CORPORATION to Hold 2022 Fourth Quarter Financial Results Conference Call on February 2nd
- IRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022
- iRadimed sees Q1 EPS 26c-28c, one est. 31c
- iRadimed sees 2023 EPS $1.23-$1.34, two est. $1.26